As President and CEO, Mr. Dentinger is responsible for both the corporate governance and the Sales and Marketing activities.

Prior to founding the company with Dr. Ismael Hidalgo in 1996, Mr. Dentinger held various business development and licensing positions within the clinical research and biotechnology industries. Mr. Dentinger and Dr. Hidalgo were 2002 recipients of the Ernst and Young Entrepreneur of the Year award.

Mr. Dentinger received his B.S. in Pharmacology from the University of California, Santa Barbara.

As Chief Scientist, Dr. Hidalgo oversees the implementation and validation of subcellular, cellular, tissue, and animal models that can be used to evaluate the ADME characteristics of compounds.

Immediately prior to founding Absorption Systems with Mr. Dentinger in 1996, Dr. Hidalgo was Senior Research Fellow in the Drug Metabolism and Pharmacokinetics Department, Rhone-Poulenc Rorer (RPR). At RPR, he worked on standard ADME-related projects and on carrier-mediated drug transport. Dr. Hidalgo has almost 20 years of pharmaceutical research experience and was a pioneer in the development of Caco-2 cells as a model system of intestinal permeability and characterized the existence of intestinal carriers in Caco-2 cells. He has published numerous scientific articles and book chapters and is a scientific reviewer for several scientific journals.

Dr. Hidalgo received his Ph.D. in Pharmaceutical Sciences from the University of Southern California and his B.S. in Pharmacy from the University of Panama. He also completed postdoctoral training on cellular models and mechanisms of drug transport in the Pharmaceutical Chemistry Department, University of Kansas, Lawrence, Kansas.

---

Dr. Owen’s responsibilities at Absorption Systems include identifying new product opportunities, implementing quality control and quality assurance programs, and consulting with customers concerning their drug development needs.

Prior to joining Absorption Systems, Dr. Owen worked at the Center for Technology Transfer at the University of Pennsylvania where his duties included evaluating and developing strategies for commercializing faculty members’ biomedical inventions. Dr Owen has also worked at companies that focused on lipid-based systems for oral, intravenous, and pulmonary drug delivery. His work at these companies resulted in several US and foreign patents.

Dr. Owen received his Ph.D. in Biophysics from Harvard University. After postdoctoral training in enzymology, he served on the faculty of the University of Rhode Island and the Harvard School of Public Health. There his research focused on nutrient transport, lipid metabolism, and cell biology.

Dr. Bhoopathy’s responsibilities include overseeing company operations, developing new business opportunities, and consulting with customers to design studies that are scientifically sound and cost-effective.

Prior to joining Absorption Systems, Dr. Bhoopathy worked at PPDI where his work focused on developing and validating GLP analytical methods and performing metabolite identification using high resolution mass spectrometry.

Dr. Bhoopathy received his Ph.D. in Pharmaceutics from Virginia Commonwealth University. His research efforts concentrated on developing high throughput techniques for in-vitro drug metabolism studies using LC/MS/MS and capillary electrophoresis with laser-induced fluorescence.

---

As Chief Financial Officer, Mr. Carr is responsible for banking relations and for the prompt and accurate reporting of financial position and results of operations to the management of the Company.

He is a Certified Public Accountant, with more than 30 years of progressively responsible experience in management, finance and accounting, many as chief financial executive of national, multi-divisional, manufacturing and service organizations.

Mr. Carr received a Bachelor of Business Administration Degree from the University of Notre Dame in 1968. He is a member of the AICPA and the New Jersey Society of Certified Public Accountants.

Dr. Bode’s responsibilities include the identification and development of new business opportunities, marketing and sales support, development of research protocols, project management, and consulting with customers, particularly in the area of in vitro drug metabolism.

Immediately prior to joining Absorption Systems, Dr. Bode was Vice President of Operations for Tissue Transformation Technologies, a leading provider of tissue-based reagents used in ADME studies. He has worked in high-throughput screening at Rhone-Poulenc Rorer and in cardiovascular pharmacology at Sterling Winthrop, where his area of expertise was cyclic nucleotide phosphodiesterases.

Dr. Bode received his Ph.D. in Pharmacology from the University of Colorado, where his research focused on the effects of ethanol on the physical and functional properties of mammalian cell membranes. His postdoctoral research at the University of California, San Diego was in the area of integration of cell signaling pathways.

As VP of Pharmacology & Toxicology Dr. Kanekal oversees scientific and regulatory aspects of all in vivo studies evaluating pharmacokinetics, safety & toxicity at our San Diego facility.

During his 17-year career at various biotechs he directed nonclinical development of small molecules and biologics, and was responsible for successful development of several drugs including Treanda (Cephalon), Accusite, Bexxar, IntraDose etc. He has 17 INDs, NDAs and BLAs under his belt and has authored about 50 publications and numerous technical reports for regulatory filings. Most recently he was Executive Director of Preclinical at Supergen, responsible for nonclinical development and IND strategy for two yrosine kinase Inhibitors. Prior to this he was in charge of non-clinical safety assessment at Chiron (Novartis), Salmedix (Cephalon), Corixa (GSK) and Matrix Pharmaceutical. He is a member of several professional organizations including American Board of Toxicology, American College of Toxicology, Society of Toxicology, AACR, AAPS, RAPS etc.

Dr. Kanekal is a veterinarian and a board-certified Toxicologist (DABT). He has a PhD in Pharmacology and Toxicology from University of California at Davis and has conducted post-doctoral research at the School of Pharmacy at University of Texas in Austin.

Dr. Bambal’s primary responsibilities include providing consultative support to customers’ ADME related drug development needs and designing studies to advance their programs. Other areas of focus include identifying areas for internal process improvement and scientific review of reports.

Prior to joining Absorption Systems, Dr. Bambal worked for SmithKline Beecham and Glaxo SmithKline in the Philadelphia region for over 12 years in the department of Drug Metabolism and Pharmacokinetics. There his group was responsible for providing ADME and PK support to drug discovery programs and making decisions regarding their progression to preclinical development.

Dr. Bambal completed his Ph.D. in Organic Chemistry from National Chemical Laboratory, Pune, India where his research focused on developing novel synthetic reactions. He also completed postdoctoral training at University College London and University of Kansas. His postdoctoral research at Kansas focused on chemical mechanisms of cytotoxicity and active site mapping of CYP enzymes.

Dr. Li’s manages the DMPK group and is responsible for research activities in Drug Metabolism, Cellular Drug Transport, and Cytotoxicity.

Prior to joining Absorption Systems, Dr. Li worked in the field of preclinical drug metabolism and pharmacokinetics at Amgen. He has over 10 years experience in the pharmaceutical industry designing and conducting ADME screening assays.

Dr. Li received his Ph.D. in Chemistry from Purdue University where his research focused on structural characterization of metalloproteins. He completed his postdoctoral research in University of North Carolina at Chapel Hill on identification of drug-resistant genes.

Dr. Marek is responsible for the planning and execution of preclinical studies at Absorption Systems.

Prior to joining Absorption Systems, he worked at Perry Scientific and at several biotechnology companies including NitroMed.

Dr. Marek received his D.V.M., Ph.D., and D.Sc. degrees from the Warsaw School of Veterinary Medicine in Poland. After completing postdoctoral training at the University of California in Los Angeles, he started his career in biotechnology. Dr. Marek has over two decades of research experience in preclinical pharmacology. His expertise encompasses multiple clinical targets in the fields of neurobiology, cardiology, and device development.

Dr. Rutar is responsible for all aspects of the quality system at Absorption Systems. He reports directly to the President.

Prior to joining Absorption Systems, Dr. Rutar worked at Union Carbide/Dow where he was involved with analyzing specialty chemicals and pharmaceutical excipients.

Dr. Rutar received his Ph.D., M.S., and B.S. in Technical Physics, from the University of Ljubljana, Slovenia. During his academic career, he developed new NMR methods that are having a lasting impact on modern analytical chemistry. In 1985, he received the highest award for scientific accomplishments in Slovenia.

Dr. Merdink is responsible for directing and performing bioanalytical method development and validation, and sample analysis, for GLP studies. He consults with clients, prepares and reviews study reports and SOPs, and monitors compliance with study protocols and SOPs.

Prior to joining Absorption Systems, Dr. Merdink directed and supervised method development, method validation and bioanalysis for preclinical and clinical client studies at BASi Northwest Laboratory Inc., (formerly LC Resources) in McMinnville, OR.

Dr. Merdink received his B.S. in Biology from the University of Minnesota and his Ph.D. in Pharmacology/Toxicology from Washington State University, where his research focused on the metabolism and toxicokinetics of haloacetic acids, trichloroethylene, chloral hydrate and trichloroethanol.

Mr. Jia manages the GLP analytical group and is responsible for designing and conducting various GLP compliant studies including BCS, stability, and toxicity studies. Mr. Jia and his group also provide analytical supports for various tissue studies.

Prior to joining Absorption Systems, Mr. Jia was a research scientist at Merck Research Laboratories where his work focused on LC/MS/MS method development and sample analysis to support preclinical toxicity and pharmacokinetic studies.

Mr. Jia received his M.S. in Medicinal Chemistry from the University of Sciences in Philadelphia and his B.S. in Chemistry from Ocean University of China.